ESR1 and metastatic neoplasm: Endocrine resistance turns out to be related to genomic and epigenetic mechanisms, such as the activating mutation of ESR1 (the most frequent one, detectable in 40% of patients with metastatic disease) and the hypermethylation of estrogen receptor promoters.